抗抑郁药合并改良森田疗法治疗躯体形式障碍临床疗效的对照研究

目的 探讨抗抑郁药合并改良森田疗法治疗躯体形式障碍的临床疗效.方法 采用单双号顺序法将78例躯体形式障碍患者分为研究组(药物合并改良森田疗法39例)和对照组(单用药物39例).应用症状自评量表(SCL-90)、艾森克个性问卷(EPQ)和大体评定量表(GAS)进行评定.结果 治疗后研究组SCL-90各项因子分分别为(1.14±0.41)分,(1.81±0.44)分,(1.27±0.41)分,(1.20±0.54)分,(1.49±0.66)分,(1.25±0.42)分,(1.09±0.48)分,(1.07±0.42)分,(1.16±0.42)分]较对照组分别为(1.46±0.44)分,(2.19±0.50)分,(1.56±0.40)分,(1.54±0.56)分,(1.85±0.48)分,(1.47±0.44)分,(1.33±0.54)分,(1.38±0.58)分,(1.38±0.45)分]差异有显著性(P＜0.05或P＜0.01);EPQ各因子分研究组E(内外向性)(7.02±4.06)分,N(神经质或情绪)(12.7±3.89)分],较对照组E(8.97±4.32)分,N(14.8±4.30)分]差异有显著性(P＜0.05);两组显效率分别为82.05%,56.41%,差异有显著性(x2=4.875,P＜0.05).结论 抗抑郁药合并改良森田疗法治疗躯体形式障碍较单纯用药疗效更佳.

Comparative study of antidepressant combined with improved Morita therapy in the treatment of somatoform disorder

Objective To explore the effects of antidepressant combined with improved Morita therapy in the treatment of somatoform disorder. Methods 78 patients with somatoform disorder were randomly divided into study group (medication combined with improved Morita therapy,39 cases) and control group (medication,39 cases). Both groups were assessed with symptom checklist 90 (SCL-90), Eysenck personality questionnaire ( EPQ )and global assessment scale ( GAS ) before and after treatment. Results After treatment, the factor scores in SCL-90 of the study group were (1. 14±0.41),(1.81 ±0.44),(1.27 ±0.41),(1.20±0.54),(1.49 ±0. 66 ), ( 1.25 ± 0. 42 ), ( 1. 09 ± 0.48), ( 1.07 ± 0. 42 ), ( 1.16 ± 0. 42 ), and that of the control group were ( 1. 46±0.44) ,(2.19±0.50),(1.56±0.40),(1.54±0.56),(1.85 ±0.48),(1.47±0.44),(1.33±0.54),( 1.38 ± 0. 58 ), ( 1.38 ± 0. 45 ), there were significant differences ( P ＜ 0. 05, P ＜ 0. 01 ). EPQ-E and EPQ-N of the study group were 7.02 ±4.06 and 12.7 ±3.89 respectively ,EPQ-E and EPQ-N of the control group were 14.8± 4.3 and 8.97 ± 4.32 respectively, there were significant differences ( P ＜ 0.05 ). The obvious effective rates of two groups were 82. 05% and 56.41% (x2 =4.875, P＜0. 05 ). Conclusion The effects of antidepressant combined with improved Morita therapy is much better in the treatment of somatoform disorder.